Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity

被引:48
作者
Garg, MB [1 ]
Sevester, JC [1 ]
Sakoff, JA [1 ]
Ackland, SP [1 ]
机构
[1] Newcastle Mater Misericordiae Hosp, Dept Med Oncol, Waratah, NSW 2298, Australia
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2002年 / 774卷 / 02期
关键词
uracil; dihydrouracil; 5-fluorouracil;
D O I
10.1016/S1570-0232(02)00239-8
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
5-Fluorouracil (5-FU) is a commonly used anti-cancer drug with notable activity in clinical practice, yet it causes significant unpredictable and often serious toxicity. Both 5-FU and uracil (U) are catabolised by dihydropyrimidine dehydrogenase (DPD) to form dihydrofluorouracil (FUH2) and dihydrouracil (UH2), respectively. A means of predicting toxicity before treatment would be more valuable. Variations in dihydropyrimidine dehydrogenase (DPD) activity between patients are at least partly responsible for variable toxicity. Measurement of the UH2 to U ratio may be a measure of pyrimidine catabolism and thus be utilised to predict subsequent toxicity. We have developed an efficient extraction and detection method using HPLC for the simultaneous measurement of UH2 and U in plasma. A single C-18 Spherisorb ODS2 (25 cm) column using isocratic elution was utilised. U, UH2 and the internal standard 4-chlorouracil were detected at wavelengths of 257, 220, and 268 nm, respectively. The chromatographic run time was 45 min which is half that of other methods. The detection limit was 0.02 muM for U and 0.1 muM for UH2 using only 0.5 ml of plasma for both compounds. The basal plasma concentrations of U and UH2 in 23 individuals ranged from 0.025 to 0.27 muM and 0.4-1.7 muM, respectively. This simple method may permit the assessment of pyrimidine catabolism, and therefore allow prediction of the toxicities associated with the use of fluorinated pyrimidines. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:223 / 230
页数:8
相关论文
共 18 条
[1]   Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography [J].
Ackland, SP ;
Garg, MB ;
Dunstan, RH .
ANALYTICAL BIOCHEMISTRY, 1997, 246 (01) :79-85
[2]   ELEVATED URINE, BLOOD AND CEREBROSPINAL-FLUID LEVELS OF URACIL AND THYMINE IN A CHILD WITH DIHYDROTHYMINE DEHYDROGENASE-DEFICIENCY [J].
BAKKEREN, JAJM ;
DEABREU, RA ;
SENGERS, RCA ;
GABREELS, FJM ;
MAAS, JM ;
RENIER, WO .
CLINICA CHIMICA ACTA, 1984, 140 (03) :247-256
[3]   Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase [J].
Bi, DQ ;
Anderson, LW ;
Shapiro, J ;
Shapiro, A ;
Grem, JL ;
Takimoto, CH .
JOURNAL OF CHROMATOGRAPHY B, 2000, 738 (02) :249-258
[4]  
CAO S, 1995, CANCER RES, V55, P6227
[5]   POPULATION STUDY OF DIHYDROPYRIMIDINE DEHYDROGENASE IN CANCER-PATIENTS [J].
ETIENNE, MC ;
LAGRANGE, JL ;
DASSONVILLE, O ;
FLEMING, R ;
THYSS, A ;
RENEE, N ;
SCHNEIDER, M ;
DEMARD, F ;
MILANO, G .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2248-2253
[6]  
FETY R, 1994, ANTICANCER RES, V14, P2347
[7]   Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer:: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage [J].
Gamelin, E ;
Boissdron-Celle, M ;
Guérin-Meyer, V ;
Delva, R ;
Lortholary, A ;
Genevieve, F ;
Larra, F ;
Ifrah, N ;
Robert, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1105-1110
[8]   A simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites [J].
Gamelin, E ;
BoisdronCelle, M ;
Larra, F ;
Robert, J .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 1997, 20 (19) :3155-3172
[9]  
Gamelin EC, 1996, CANCER, V77, P441, DOI 10.1002/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO
[10]  
2-N